Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Base estimates & working
1.3 Forecast calculations
1.4 Data validation
1.5 Data Sources
1.5.1 Secondary
1.5.1.1 Paid Sources
1.5.1.2 Unpaid Sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 PCR & NGS based Diagnostic testing industry 3600 synopsis, 2016 – 2027
2.1.1 Business trends
2.1.2 Product trends
2.1.3 End-use trends
2.1.4 Regional trends
Chapter 3 PCR & NGS based Diagnostic Testing Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 – 2027
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising importance of diagnostic tests in virus detection
3.3.1.2 Growing usage of NGS technology by pharmaceutical and biopharmaceutical companies
3.3.1.3 Increasing research and developmental (R&D) activities in developed economies
3.3.1.4 High risk of infection in geriatric population
3.3.2 Industry pitfalls and challenges
3.3.2.1 High cost of diagnostic testing
3.4 Growth potential analysis
3.4.1 By product
3.4.2 By end-use
3.5 COVID-19 impact analysis
3.5.1 Impact of COVID-19 on global PCR & NGS based diagnostic testing market
3.5.2 Impact of COVID-19 on industry value chain
3.5.2.1 Research and development
3.5.2.2 Manufacturing
3.5.2.3 Marketing
3.5.2.4 Supply
3.5.3 Impact of COVID-19 on industry competition
3.5.3.1 Strategy
3.5.3.2 Product portfolio
3.5.3.3 Business growth
3.6 Porter’s analysis
3.7 Competitive landscape, 2020
3.7.1 Company matrix analysis, 2020
3.7.2 Manufacturing scenario
3.7.2.1 List of equipment manufacturers in the U.S., Europe, and Asia
3.7.2.2 List of consumable manufacturers in the U.S., Europe, and Asia
3.8 Consumer dynamics: equipment purchase vs leasing
3.9 Supply chain analysis
3.10 PESTEL analysis
3.11 Technology roadmap and future trends
Chapter 4 PCR & NGS based Diagnostic Testing Market, By Product
4.1 Key segment trends
4.2 Consumables
4.2.1 Market size, by region, 2016 – 2027
4.3 Equipment
4.3.1 Market size, by region, 2016 – 2027
4.4 Labware
4.4.1 Market size, by region, 2016 – 2027
Chapter 5 PCR & NGS based Diagnostic Testing Market, By End-use
5.1 Key segment trends
5.2 Hospitals and clinics
5.2.1 Market size, by region, 2016 – 2027
5.3 Diagnostic centers
5.3.1 Market size, by region, 2016 – 2027
5.4 Ambulatory settings
5.4.1 Market size, by region, 2016 – 2027
5.5 Others
5.5.1 Market size, by region, 2016 – 2027
Chapter 6 PCR & NGS based Diagnostic Testing Market, By Region
6.1 Key regional trends
6.2 North America
6.2.1 Market size, by country, 2016 – 2027
6.2.2 Market size, by product, 2016 – 2027
6.2.3 Market size, by end-use, 2016 – 2027
6.2.4 U.S.
6.2.4.1 Market size, by product, 2016 – 2027
6.2.4.2 Market size, by end-use, 2016 – 2027
6.2.5 Canada
6.2.5.1 Market size, by product, 2016 – 2027
6.2.5.2 Market size, by end-use, 2016 – 2027
6.3 Europe
6.3.1 Market size, by country, 2016 – 2027
6.3.2 Market size, by product, 2016 – 2027
6.3.3 Market size, by end-use, 2016 – 2027
6.3.4 UK
6.3.4.1 Market size, by product, 2016 – 2027
6.3.4.2 Market size, by end-use, 2016 – 2027
6.3.5 France
6.3.5.1 Market size, by product, 2016 – 2027
6.3.5.2 Market size, by end-use, 2016 – 2027
6.3.6 Germany
6.3.6.1 Market size, by product, 2016 – 2027
6.3.6.2 Market size, by end-use, 2016 – 2027
6.3.7 Italy
6.3.7.1 Market size, by product, 2016 – 2027
6.3.7.2 Market size, by end-use, 2016 – 2027
6.3.8 Spain
6.3.8.1 Market size, by product, 2016 – 2027
6.3.8.2 Market size, by end-use, 2016 – 2027
6.4 Asia Pacific
6.4.1 Market size, by country, 2016 – 2027
6.4.2 Market size, by product, 2016 – 2027
6.4.3 Market size, by end-use, 2016 – 2027
6.4.4 India
6.4.4.1 Market size, by product, 2016 – 2027
6.4.4.2 Market size, by end-use, 2016 – 2027
6.4.5 China
6.4.5.1 Market size, by product, 2016 – 2027
6.4.5.2 Market size, by end-use, 2016 – 2027
6.4.6 Japan
6.4.6.1 Market size, by product, 2016 – 2027
6.4.6.2 Market size, by end-use, 2016 – 2027
6.4.7 Australia
6.4.7.1 Market size, by product, 2016 – 2027
6.4.7.2 Market size, by end-use, 2016 – 2027
6.5 Latin America
6.5.1 Market size, by country, 2016 – 2027
6.5.2 Market size, by product, 2016 – 2027
6.5.3 Market size, by end-use, 2016 – 2027
6.5.4 Brazil
6.5.4.1 Market size, by product, 2016 – 2027
6.5.4.2 Market size, by end-use, 2016 – 2027
6.5.5 Mexico
6.5.5.1 Market size, by product, 2016 – 2027
6.5.5.2 Market size, by end-use, 2016 – 2027
6.6 MEA
6.6.1 Market size, by country, 2016 – 2027
6.6.2 Market size, by product, 2016 – 2027
6.6.3 Market size, by end-use, 2016 – 2027
6.6.4 Saudi Arabia
6.6.4.1 Market size, by product, 2016 – 2027
6.6.4.2 Market size, by end-use, 2016 – 2027
6.6.5 South Africa
6.6.5.1 Market size, by product, 2016 – 2027
6.6.5.2 Market size, by end-use, 2016 – 2027
Chapter 7 Company Profiles
7.1 Strategy dashboard, 2020
7.2 Agilent Technologies, Inc
7.2.1 Business Overview
7.2.2 Financial data
7.2.3 Product landscape
7.2.4 Strategic outlook
7.2.5 SWOT analysis
7.3 Bio-Rad Laboratories, Inc
7.3.1 Business overview
7.3.2 Financial data
7.3.3 Product landscape
7.3.4 SWOT analysis
7.4 Eppendorf AG
7.4.1 Business Overview
7.4.2 Financial data
7.4.3 Product Landscape
7.4.4 SWOT analysis
7.5 Fluotics
7.5.1 Business overview
7.5.2 Financial data
7.5.3 Product landscape
7.5.4 SWOT analysis
7.6 Hamilton Company
7.6.1 Business overview
7.6.2 Financial data
7.6.3 Product landscape
7.6.4 Strategic outlook
7.6.5 SWOT analysis
7.7 Illumina, Inc
7.7.1 Business Overview
7.7.2 Financial data
7.7.3 Product landscape
7.7.4 SWOT analysis
7.8 Integra LifeScience Holdings Corporation
7.8.1 Business overview
7.8.2 Financial data
7.8.3 Product landscape
7.8.4 Strategic outlook
7.8.5 SWOT analysis
7.9 MGI Tech Co , Ltd
7.9.1 Business overview
7.9.2 Financial data
7.9.3 Product landscape
7.9.4 SWOT analysis
7.10 Mascon, Inc.
7.10.1 Business Overview
7.10.2 Financial data
7.10.3 Product Landscape
7.10.4 SWOT analysis
7.11 Qiagen
7.11.1 Business Overview
7.11.2 Financial data
7.11.3 Product Landscape
7.11.4 Strategy outlook
7.11.5 SWOT analysis
7.12 Roche Diagnostics
7.12.1 Business Overview
7.12.2 Financial data
7.12.3 Product Landscape
7.12.4 Strategy outlook
7.12.5 SWOT analysis
7.13 Thermo Fisher Scientific
7.13.1 Business Overview
7.13.2 Financial data
7.13.3 Product Landscape
7.13.4 Strategy outlook
7.13.5 SWOT analysis
7.14 Thomas Scientific (The Carlyle Group)
7.14.1 Business Overview
7.14.2 Financial data
7.14.3 Product Landscape
7.14.4 Strategy outlook
7.14.5 SWOT analysis
7.15 VWR International (Avantor, Inc.)
7.15.1 Business Overview
7.15.2 Financial data
7.15.3 Product Landscape
7.15.4 Strategy outlook
7.15.5 SWOT analysis
